Exploring the role of EZH2 in RNA editing related to prostate cancer
Official title: A novel role for EZH2 in A-to-I RNA editing in prostate cancer
Funded at Northwestern University at Chicago · NIH-11026357 · Data updated 2026-11-12
This study is looking at how a protein called EZH2 affects RNA in prostate cancer, with the hope of finding new ways to improve treatment for patients with advanced disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | February 5, 2024 |
| Project end | January 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $589,741 |
| NIH project number | 5R01CA278832-02 |
| Project ID | NIH-11026357 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with advanced prostate cancer, particularly those who have shown resistance to current therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those who do not have advanced disease may not benefit from this research.
What this research studies
This research investigates how the EZH2 protein, which is known to modify DNA, also influences RNA editing in prostate cancer. By understanding the role of EZH2 in altering RNA, the study aims to identify new therapeutic targets that could improve treatment outcomes for patients with advanced prostate cancer. The approach includes analyzing the expression levels of EZH2 and its impact on RNA stability and mutations, which could lead to better strategies for managing the disease. Patients may benefit from insights that could lead to more effective treatments based on their specific cancer characteristics.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve survival rates for patients with advanced prostate cancer.
How similar studies have gone: Previous research has shown promising results in targeting epigenetic modifications in cancer, suggesting that this approach could yield significant advancements.
Where this research is happening
-
Northwestern University at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Cao, Qi — Northwestern University at Chicago
- Study coordinator: Cao, Qi
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.